Compare Stocks: BDRX, EVGN, LIMN, and TCRT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$0.81 -6.5%	$1.92	$0.78 ▼ $59.40	$836K	1.24	476,647 shs	104,535 shs
EVGN Evogene	$0.54 -2.4%	$0.53	$0.37 ▼ $1.50	$4.68M	1.4	905,979 shs	158,754 shs
LIMN Liminatus Pharma	$3.86 -8.7%	$5.70	$3.80 ▼ $154.50	$5.17M	5.34	398,490 shs	51,327 shs
TCRT Alaunos Therapeutics	$1.70 +5.9%	$1.98	$1.55 ▼ $4.59	$4.32M	-1	16,723 shs	12,911 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	0.00%	-31.65%	-34.23%	-73.85%	-96.87%
EVGN Evogene	0.00%	-2.29%	+16.69%	-19.53%	-56.03%
LIMN Liminatus Pharma	0.00%	-18.02%	-17.86%	-53.03%	-96.88%
TCRT Alaunos Therapeutics	0.00%	-8.81%	-14.63%	-44.08%	-24.65%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$0.81 -6.5%	$1.92	$0.78 ▼ $59.40	$836K	1.24	476,647 shs	104,535 shs
EVGN Evogene	$0.54 -2.4%	$0.53	$0.37 ▼ $1.50	$4.68M	1.4	905,979 shs	158,754 shs
LIMN Liminatus Pharma	$3.86 -8.7%	$5.70	$3.80 ▼ $154.50	$5.17M	5.34	398,490 shs	51,327 shs
TCRT Alaunos Therapeutics	$1.70 +5.9%	$1.98	$1.55 ▼ $4.59	$4.32M	-1	16,723 shs	12,911 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	0.00%	-31.65%	-34.23%	-73.85%	-96.87%
EVGN Evogene	0.00%	-2.29%	+16.69%	-19.53%	-56.03%
LIMN Liminatus Pharma	0.00%	-18.02%	-17.86%	-53.03%	-96.88%
TCRT Alaunos Therapeutics	0.00%	-8.81%	-14.63%	-44.08%	-24.65%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	1.00	Sell	N/A	N/A
EVGN Evogene	1.00	Sell	N/A	N/A
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BDRX, EVGN, LIMN, and TCRT Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/20/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	EVGN Evogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/18/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/3/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	$470K	1.77	N/A	N/A	$110.30 per share	0.01
EVGN Evogene	$1.66M	2.78	N/A	N/A	$1.37 per share	0.39
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	($18.13) per share	N/A
TCRT Alaunos Therapeutics	$3K	1,433.15	N/A	N/A	$0.93 per share	1.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$8.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/11/2026 (Estimated)
EVGN Evogene	-$8.48M	-$0.91	N/A	N/A	N/A	-694.18%	-156.53%	-86.80%	11/18/2026 (Estimated)
LIMN Liminatus Pharma	-$10.21M	-$23.50	N/A	N/A	N/A	N/A	N/A	-256.58%	N/A
TCRT Alaunos Therapeutics	-$4.18M	-$1.91	N/A	N/A	N/A	N/A	-232.60%	-158.99%	11/17/2026 (Estimated)

Latest BDRX, EVGN, LIMN, and TCRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	LIMN Liminatus Pharma	N/A	-$1.50	N/A	-$0.03	N/A	N/A
8/14/2026	Q2 2026	TCRT Alaunos Therapeutics	N/A	-$0.41	N/A	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	N/A	2.03	2.03
EVGN Evogene	N/A	3.57	3.54
LIMN Liminatus Pharma	N/A	1.12	1.12
TCRT Alaunos Therapeutics	N/A	0.77	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
EVGN Evogene	10.40%
LIMN Liminatus Pharma	N/A
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
EVGN Evogene	7.40%
LIMN Liminatus Pharma	19.40%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	1.03 million	1.03 million	Not Optionable
EVGN Evogene	140	8.72 million	8.07 million	No Data
LIMN Liminatus Pharma	N/A	1.34 million	1.08 million	N/A
TCRT Alaunos Therapeutics	40	2.54 million	2.13 million	No Data

BDRX, EVGN, LIMN, and TCRT Headlines

Recent News About These Companies

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026 | markets.businessinsider.com

Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | finanznachrichten.de

Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers

May 26, 2026 | msn.com

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | globenewswire.com

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026 | globenewswire.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

Alaunos Reports Positive Preclinical Data for Obesity Candidate

March 2, 2026 | tipranks.com

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026 | globenewswire.com

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

December 23, 2025 | tipranks.com

Alaunos Therapeutics files to sell 327,740 shares of common for holders

October 22, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, EVGN, LIMN, and TCRT Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$0.81 -0.06 (-6.50%)

As of 04:00 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Evogene NASDAQ:EVGN

$0.54 -0.01 (-2.38%)

As of 04:00 PM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Liminatus Pharma NASDAQ:LIMN

$3.86 -0.37 (-8.75%)

As of 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Alaunos Therapeutics NASDAQ:TCRT

$1.70 +0.10 (+5.92%)

As of 04:00 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, EVGN, LIMN, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, EVGN, LIMN, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, EVGN, LIMN, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, EVGN, LIMN, and TCRT Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

Evogene NASDAQ:EVGN

Liminatus Pharma NASDAQ:LIMN

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, EVGN, LIMN, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, EVGN, LIMN, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, EVGN, LIMN, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, EVGN, LIMN, and TCRT Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

Evogene NASDAQ:EVGN

Liminatus Pharma NASDAQ:LIMN

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools